

Safeguarding public health
Defective Medicines Report Centre
151 Buckingham Palace Road
London
SW1W 9SZ
Telephone +44 (0)20 3080 6574



MHRA

DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours
Pharmacy, Clinic and Wholesaler Level Recall

Date: 27 February 2013

EL (13)A/06

Our Ref: MDR 56-02/13

Dear Healthcare Professional,

Typharm Limited

GoldenEye 0.15% w/w eye ointment
(Dibrompropamide Isetionate)

PL 00551/0004

Batch Number	Expiry Date	Pack Size	First Distributed
102732	10/2015	1 x 5g	24/01/2013

Cambridge Healthcare Supplies Limited, distributors of GoldenEye 0.15% w/w eye ointment on behalf of Marketing Authorisation Holder, Typharm Limited are recalling all remaining stock of this batch to Pharmacy, clinic and wholesaler level, due to an issue with seal integrity and compromised sterility assurance, introduced during the filling process.

Remaining stocks of the affected batches should be quarantined and returned to Cambridge Healthcare Supplies Limited at the address below for credit.

Cambridge Healthcare Supplies Limited
Freepost RSSX-TSLG-XSET
Chestnut Drive
Wymondham
NR18 9SB

For medical information enquiries please contact Cambridge Healthcare Supplies Limited by telephone on 01953 607856 or by email on medinfo@cambridge-healthcare.co.uk

Contd/...

MHRA Distribution:

Regional Contacts for NHS Trusts and Provider Units
Chief Pharmacists: England, Scotland, Wales, Northern Ireland
Prison Health Policy Unit (DH)
Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special Hospitals
Healthcare Commission for distribution to Independent Health Care Establishments
Primary Care Trusts (England)

Medicines and Healthcare products Regulatory Agency (MHRA)
151 Buckingham Palace Road London SW1W 9SZ UK
T 020 3080 6000 www.mhra.gov.uk

An executive agency of the Department of Health



Date: 27 February 2013

EL (13)A/06

Our Ref: MDR 56-02/13

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary Care Trusts are asked to forward this to relevant clinics and to General Practitioners and Community Pharmacists for information.

Yours faithfully

Adam Burgess

MHRA DMRC Manager